Best Peptides for Weight Loss in 2026: Evidence-Based Rankings

Overview

The landscape of peptide-based weight management has expanded rapidly, driven by the clinical success of GLP-1 receptor agonists and related incretin therapies. This ranking evaluates seven of the most researched peptides associated with weight loss, ordered by the strength and quality of available evidence. These compounds range from FDA-approved medications backed by large randomized controlled trials to preclinical research chemicals with only animal data. The distinction matters enormously — for regulatory status, safety confidence, and accessibility. This article is strictly educational and does not constitute a recommendation to use any compound. Weight management decisions should always involve a qualified healthcare provider.

How Peptides Influence Body Weight

Peptides associated with weight loss generally work through one or more of three broad mechanisms. The first and most clinically validated is appetite and satiety signaling: GLP-1 and GIP receptor agonists reduce hunger, slow gastric emptying, and promote feelings of fullness, leading to decreased caloric intake. The second is energy expenditure: glucagon receptor activation and growth hormone-releasing hormone (GHRH) analogs may increase metabolic rate, thermogenesis, and fat oxidation. The third is direct fat metabolism modulation: some compounds target adipose tissue directly, influencing lipolysis, fat cell differentiation, or metabolic enzyme activity. The most effective weight loss peptides in clinical trials combine multiple mechanisms — tirzepatide activates both GIP and GLP-1 receptors, while retatrutide adds glucagon receptor activation to the mix. Understanding these mechanisms helps contextualize why some peptides produce dramatic weight loss in clinical trials while others show modest or uncertain effects.

#1: Semaglutide (Wegovy / Ozempic)

Semaglutide is a GLP-1 receptor agonist and was the first peptide-based therapy to demonstrate transformative weight loss in large-scale clinical trials. Approved by the FDA as Wegovy for chronic weight management and as Ozempic for type 2 diabetes, semaglutide works primarily by mimicking the incretin hormone GLP-1 — reducing appetite, slowing gastric emptying, and improving glycemic control. The STEP clinical trial program, which enrolled thousands of participants across multiple studies, demonstrated mean body weight reductions of 14.9% to 16.9% at 68 weeks with the 2.4 mg weekly dose. In the STEP 1 trial specifically, 86% of participants lost at least 5% of body weight and approximately one-third lost 20% or more. The most common side effects are gastrointestinal: nausea (reported in approximately 44% of participants), diarrhea, vomiting, and constipation. These effects are typically most pronounced during dose escalation and tend to diminish over time. Semaglutide is administered as a once-weekly subcutaneous injection.

• Evidence level: Strong — FDA-approved, supported by multiple large phase 3 RCTs
• Mean weight loss: 14.9–16.9% at 68 weeks (STEP program)
• Mechanism: GLP-1 receptor agonist (appetite reduction + slowed gastric emptying)
• Administration: Once-weekly subcutaneous injection (2.4 mg maintenance dose)
• Regulatory status: FDA-approved for chronic weight management (Wegovy) and type 2 diabetes (Ozempic)
• Key consideration: Requires ongoing use; weight regain is common after discontinuation

#2: Tirzepatide (Zepbound / Mounjaro)

Tirzepatide is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly that has demonstrated the highest weight loss of any currently approved anti-obesity medication. Approved as Zepbound for weight management and Mounjaro for type 2 diabetes, tirzepatide activates both GIP and GLP-1 receptors simultaneously, which appears to produce additive metabolic benefits beyond GLP-1 agonism alone. In the SURMOUNT-1 trial, participants receiving the highest dose (15 mg) achieved a mean weight loss of 22.5% at 72 weeks — significantly exceeding semaglutide's results in comparable trials. Approximately 63% of participants on the 15 mg dose lost at least 20% of their body weight. The side effect profile is similar to semaglutide, with nausea (reported in 24–33% depending on dose), diarrhea, and vomiting being most common during dose titration. Tirzepatide is administered as a once-weekly subcutaneous injection with dose escalation from 2.5 mg to a maximum of 15 mg.

• Evidence level: Strong — FDA-approved, supported by large phase 3 RCTs (SURMOUNT program)
• Mean weight loss: Up to 22.5% at 72 weeks (SURMOUNT-1, 15 mg dose)
• Mechanism: Dual GIP/GLP-1 receptor agonist (enhanced appetite reduction + metabolic effects)
• Administration: Once-weekly subcutaneous injection (up to 15 mg maintenance)
• Regulatory status: FDA-approved for weight management (Zepbound) and type 2 diabetes (Mounjaro)
• Key consideration: Cross-trial data suggests superiority over semaglutide, though head-to-head data is limited

#3: Retatrutide (Investigational)

Retatrutide (LY3437943) is a first-in-class triple-hormone receptor agonist developed by Eli Lilly that targets GIP, GLP-1, and glucagon receptors simultaneously. It is not yet approved and is currently being evaluated in the phase 3 TRIUMPH clinical trial program. In phase 2 trials published in the New England Journal of Medicine, retatrutide produced the highest weight loss ever reported for an anti-obesity drug: up to 24.2% mean body weight reduction at 48 weeks with the 12 mg dose. More than 90% of participants in the highest-dose group lost at least 10% of body weight, and roughly 75% lost at least 20%. The addition of glucagon receptor agonism to the GIP/GLP-1 backbone may increase hepatic energy expenditure and fat oxidation — a mechanism distinct from the appetite-reduction effects of GLP-1 agonists. Side effects in phase 2 were predominantly gastrointestinal and similar to other incretin therapies. Retatrutide is not commercially available and can currently only be accessed through clinical trial enrollment.

• Evidence level: Strong phase 2 data; awaiting phase 3 confirmation
• Mean weight loss: Up to 24.2% at 48 weeks (phase 2, 12 mg dose)
• Mechanism: Triple GIP/GLP-1/glucagon receptor agonist (appetite + energy expenditure + fat oxidation)
• Administration: Once-weekly subcutaneous injection
• Regulatory status: Investigational — phase 3 trials ongoing (TRIUMPH program)
• Key consideration: Not available for purchase; phase 3 results needed to confirm efficacy and safety

#4: Tesamorelin (Egrifta)

Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that stimulates pulsatile growth hormone secretion from the pituitary gland. It is FDA-approved under the brand name Egrifta specifically for the reduction of excess abdominal fat (visceral adipose tissue) in HIV-infected patients with lipodystrophy — making it the only peptide on this list approved for a fat-reduction indication other than GLP-1/GIP agonists. In clinical trials for its approved indication, tesamorelin reduced visceral adipose tissue by approximately 15–18% over 26 weeks. Unlike GLP-1 agonists, tesamorelin does not primarily work through appetite suppression; instead, it increases growth hormone levels, which promotes lipolysis and may shift body composition toward less fat and more lean mass. It requires daily subcutaneous injection rather than weekly dosing. Tesamorelin's evidence for general obesity treatment (outside HIV lipodystrophy) is limited, and its off-label use for weight loss in the general population is not well-studied in controlled trials.

• Evidence level: Strong for visceral fat reduction in HIV lipodystrophy (FDA-approved indication); moderate for general weight management
• Mean fat reduction: 15–18% visceral adipose tissue reduction at 26 weeks (approved indication)
• Mechanism: GHRH analog — stimulates endogenous growth hormone release, promotes lipolysis
• Administration: Daily subcutaneous injection (2 mg)
• Regulatory status: FDA-approved for HIV-associated lipodystrophy (Egrifta); off-label use for other indications
• Key consideration: Targets visceral fat specifically; less evidence for overall weight loss vs GLP-1 agonists

#5: AOD-9604

AOD-9604 is a synthetic peptide fragment corresponding to amino acids 177–191 of human growth hormone (hGH), with an added tyrosine residue. It was designed to isolate the fat-reducing properties of growth hormone without its growth-promoting or diabetogenic effects. AOD-9604 reached phase 2 clinical trials for obesity treatment, where it showed modest fat reduction compared to placebo in some study arms, though the results were not considered strong enough to advance to phase 3 trials. The proposed mechanism involves stimulation of lipolysis and inhibition of lipogenesis through beta-3 adrenergic receptor pathways, without affecting IGF-1 levels or insulin sensitivity — which would theoretically avoid the metabolic risks associated with exogenous growth hormone use. AOD-9604 has a more limited evidence base than the GLP-1/GIP agonists above, and its clinical development for obesity has not progressed since the early 2000s. It is available through some compounding pharmacies and peptide suppliers but is not FDA-approved for any indication.

• Evidence level: Moderate — phase 2 human data available, but clinical development stalled
• Observed effect: Modest fat reduction in some phase 2 study arms
• Mechanism: hGH fragment (amino acids 177-191) — stimulates lipolysis without IGF-1 elevation
• Administration: Subcutaneous injection (typically discussed at 250–300 mcg daily in practitioner settings)
• Regulatory status: Not FDA-approved; no active clinical development program
• Key consideration: Limited human data; clinical development did not advance past phase 2

#6: 5-Amino-1MQ

5-Amino-1MQ is a small-molecule peptide that inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that plays a role in cellular energy metabolism and fat storage. NNMT is overexpressed in adipose tissue of obese individuals, and inhibiting it has been shown to increase NAD+ levels, activate fat metabolism, and promote the conversion of white adipose tissue to metabolically active beige adipose tissue in animal models. In preclinical studies, NNMT inhibition reduced body weight and improved metabolic markers in diet-induced obese mice without affecting food intake — suggesting a mechanism distinct from appetite suppression. However, 5-Amino-1MQ has no published human clinical trial data. All evidence comes from animal studies and in vitro experiments. The translation from mouse models to human efficacy is uncertain, and the safety profile in humans has not been formally evaluated. It is sold as a research chemical by some peptide suppliers but is not approved for human use.

• Evidence level: Preliminary — preclinical animal data only, no human trials
• Animal data: Reduced body weight and improved metabolic markers in obese mice
• Mechanism: NNMT inhibitor — raises NAD+ in adipose tissue, promotes white-to-beige fat conversion
• Administration: Oral capsule (commonly discussed at 50–100 mg daily in online communities)
• Regulatory status: Not FDA-approved; no clinical trials in progress
• Key consideration: Promising preclinical mechanism but zero human efficacy or safety data

#7: MOTS-c

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a mitochondrial-derived peptide that has attracted research interest for its potential exercise-mimetic and metabolic effects. In animal studies, MOTS-c activates AMPK (AMP-activated protein kinase), a key cellular energy sensor, leading to increased glucose uptake, enhanced fatty acid oxidation, and improved insulin sensitivity. Mice treated with MOTS-c showed resistance to diet-induced obesity and improved metabolic parameters even without changes in physical activity. MOTS-c is endogenously produced in small quantities and declines with age, which has led researchers to hypothesize that supplementation could restore youthful metabolic function — though this remains speculative. Like 5-Amino-1MQ, MOTS-c has no published human clinical trial data for weight loss. A small study examined MOTS-c in the context of exercise performance in humans, but weight loss was not a primary endpoint. It is classified as a research chemical and is not approved for any clinical use.

• Evidence level: Preliminary — preclinical animal data only for weight management
• Animal data: Resistance to diet-induced obesity and improved metabolic markers
• Mechanism: Mitochondrial peptide — AMPK activator, exercise mimetic, enhanced fatty acid oxidation
• Administration: Subcutaneous injection (commonly discussed at 5–10 mg weekly in online communities)
• Regulatory status: Not FDA-approved; very limited human research (not for weight loss)
• Key consideration: Intriguing longevity and metabolic research, but far from clinical application for weight loss

How to Evaluate Weight Loss Peptide Claims

The peptides listed above span a wide range of evidence quality, from FDA-approved medications with thousands of trial participants to research chemicals tested only in mice. When evaluating any weight loss peptide claim, consider these factors: First, what is the study design? Randomized controlled trials (RCTs) in humans provide the strongest evidence. Observational studies, case reports, and anecdotal forum posts are progressively weaker. Second, how large was the study? Phase 3 trials for semaglutide and tirzepatide enrolled thousands; phase 2 data for retatrutide involved hundreds. Preclinical compounds like 5-Amino-1MQ and MOTS-c have zero human trial participants. Third, has the result been replicated? Multiple independent research groups confirming a finding is far more reliable than a single lab's results. Fourth, what is the regulatory status? FDA approval requires demonstration of both efficacy and safety in rigorous trials. Compounds that never advanced past early phases may have failed for efficacy, safety, or commercial reasons. Fifth, be cautious about extrapolating animal data to humans — metabolic differences between species are significant, and many promising animal results do not translate to human benefit.

• Randomized controlled trials (RCTs) > observational studies > case reports > anecdotal reports
• Larger sample sizes and longer durations provide more reliable estimates
• Independent replication by multiple research groups strengthens confidence
• FDA approval requires demonstration of both efficacy and safety
• Animal data provides hypotheses, not conclusions about human efficacy
• Publication bias: positive results are more likely to be published than negative ones
• Industry-funded trials should be interpreted alongside independent research

Important Safety and Legal Considerations

The regulatory and safety landscape for weight loss peptides is complex. Semaglutide, tirzepatide, and tesamorelin are FDA-approved medications available by prescription for specific indications. These have undergone rigorous safety evaluation through clinical trials involving thousands of participants, with known and monitored side effect profiles. Retatrutide is investigational and only accessible through clinical trial enrollment — it has not completed the regulatory review process. AOD-9604, 5-Amino-1MQ, and MOTS-c are not approved for any medical use and are sold as research chemicals by unregulated suppliers. Products from these sources may have purity, contamination, or dosing accuracy issues that pose health risks beyond the compounds themselves. Self-administering any peptide without medical supervision carries inherent risks, including drug interactions, unrecognized contraindications, and the inability to monitor for adverse effects. Anyone considering peptide therapy for weight management should consult a licensed healthcare provider who can evaluate their individual medical history, discuss FDA-approved options, and provide appropriate monitoring.

• FDA-approved options (semaglutide, tirzepatide, tesamorelin) have the most well-characterized safety profiles
• Investigational compounds (retatrutide) are only available through authorized clinical trials
• Research chemicals (AOD-9604, 5-Amino-1MQ, MOTS-c) have no regulatory quality oversight for human use
• Gray-market peptide products may contain contaminants, incorrect dosages, or mislabeled compounds
• Medical supervision is essential for monitoring side effects, drug interactions, and metabolic markers
• Weight regain after discontinuation is well-documented for GLP-1 agonists — long-term management strategies matter

Explore Next

References

1. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) (2021) — PubMed
2. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) (2022) — PubMed
3. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial (2023) — PubMed
4. Tesamorelin for the Treatment of Visceral Adiposity in HIV-Infected Patients (2010) — PubMed
5. AOD9604 — A Novel Anti-Obesity Compound: Studies in Animal Models (2001) — PubMed
6. NNMT Inhibition Reduces Body Weight and Improves Metabolic Parameters in Diet-Induced Obese Mice (2020) — PubMed
7. The Mitochondrial-Derived Peptide MOTS-c: A Player in Exceptional Longevity? (2015) — PubMed
8. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6) (2016) — PubMed